Several analysts have recently updated their ratings and price targets for Astrazeneca PLC (NYSE: AZN):

  • 9/13/2016 – Astrazeneca PLC was downgraded by analysts at BNP Paribas from an “outperform” rating to a “neutral” rating.
  • 9/12/2016 – Astrazeneca PLC was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $36.15 price target on the stock.
  • 9/12/2016 – Astrazeneca PLC was upgraded by analysts at Jefferies Group from a “hold” rating to a “buy” rating.
  • 9/11/2016 – Astrazeneca PLC had its “buy” rating reaffirmed by analysts at Berenberg Bank.
  • 9/8/2016 – Astrazeneca PLC was given a new $41.40 price target on by analysts at Bank of America Corp.. They now have a “buy” rating on the stock.
  • 9/8/2016 – Astrazeneca PLC had its “buy” rating reaffirmed by analysts at Deutsche Bank AG.
  • 9/3/2016 – Astrazeneca PLC had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 8/29/2016 – Astrazeneca PLC was upgraded by analysts at Argus from a “hold” rating to a “buy” rating. They now have a $38.00 price target on the stock.
  • 8/26/2016 – Astrazeneca PLC had its “hold” rating reaffirmed by analysts at Beaufort Securities.
  • 8/11/2016 – Astrazeneca PLC had its “hold” rating reaffirmed by analysts at Beaufort Securities.
  • 8/10/2016 – Astrazeneca PLC had its “buy” rating reaffirmed by analysts at Citigroup Inc..
  • 8/10/2016 – Astrazeneca PLC had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 8/8/2016 – Astrazeneca PLC had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald.
  • 8/8/2016 – Astrazeneca PLC had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 7/31/2016 – Astrazeneca PLC had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 7/28/2016 – Astrazeneca PLC had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald.
  • 7/27/2016 – Astrazeneca PLC had its “buy” rating reaffirmed by analysts at Citigroup Inc..
  • 7/27/2016 – Astrazeneca PLC had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 7/22/2016 – Astrazeneca PLC was upgraded by analysts at TheStreet from a “hold” rating to a “buy” rating.

Shares of Astrazeneca PLC (NYSE:AZN) opened at 33.52 on Tuesday. The company has a market cap of $84.81 billion, a PE ratio of 38.31 and a beta of 0.77. The stock’s 50 day moving average is $33.49 and its 200-day moving average is $30.37. Astrazeneca PLC has a one year low of $26.97 and a one year high of $35.04.

Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.76 by $0.07. The business earned $5.60 billion during the quarter, compared to the consensus estimate of $5.56 billion. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The company’s quarterly revenue was down 4.0% on a year-over-year basis. During the same quarter last year, the company earned $1.21 earnings per share. Equities research analysts expect that Astrazeneca PLC will post $2.97 earnings per share for the current year.

The firm also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were issued a $0.44 dividend. The ex-dividend date of this dividend was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio is presently 78.29%.

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

5 Day Chart for NYSE:AZN

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.